Dr. Volker Hoffmann MD

Partner/Owner, Diagnostic Imaging Center

GLG News by Dr. Volker Hoffmann MD, Partner/Owner

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

NSF (Nephrogenic Systemic Fibrosis) - Gadoxetic Acid (Primovist)

October 9, 2007

Analysis of:Study Finds NSF More Common Than Previously Reported | www.dimag.com

Nephrogenic systemic fibrosis is becoming a severe problem for radiologist and industry as it may prevent physicians from using gadolinium containing contrast agents fearing that they induce nephrogenic systemic fibrosis even in patients without known kidney disease. A stable contrast agent with almost no release of gadolinium may be a solution: gadoxetic acid, sold in Europe and Asia as Primovist.

IMDS - CTML - Value without contrast agents?

May 14, 2007

Analysis of:Imaging Diagnostic Systems Breast Scanner Performance Upgrade Program Nearing Completion | www.medicalnewstoday.com

The recent upgrade of the Computed Tomography Laser Mammography (CTLM(R)) system will only added minor details. The question whether this system without any contrast agent is of any value has not been answered so far.

Impropved pancreatic duct imaging in MR - small market for Secretin

May 14, 2007

Analysis of:Repligen Reports Positive Phase 2 Clinical Trial Results Of Secretin For MRI Imaging Of The Pancreas | www.medicalnewstoday.com

Pancreatic duct imaging is currently done with a heavily weighted T2 sequence that requires water in the duct for imaging. Increased production of pancreatic juice may make imaging easier. This is however a very small niche market which by itself will not allow survival of RG1068.

Page : 11 to 3 of 3

Subscribe to Updates

By RSS